Identification of a novel alternative splicing isoform of the Hippo kinase STK3 /MST2 with impaired kinase and cell growth suppressing activities
Ana Maria Rodrigues,Ana Paula Zen Petisco Fiore,Gabriela D. A. Guardia,Rebeka Tomasin,André Azevedo Reis Teixeira,Ricardo Jose Giordano,Deborah Schechtman,Michele Pagano,Pedro A. F. Galante,Alexandre Bruni-Cardoso
DOI: https://doi.org/10.1038/s41388-024-03104-2
IF: 8.756
2024-08-24
Oncogene
Abstract:Mammalian Ste-20-like Kinases 1 and 2 (MST1/2) are core serine-threonine kinases of the Hippo pathway regulating several cellular processes, including cell cycle arrest and cell death. Here, we discovered a novel alternative splicing variant of the MST2 encoding gene, STK3 , in malignant cells and tumor datasets. This variant, named STK3 ∆7 or MST2 ∆7 (for mRNA or protein, respectively), resulted from the skipping of exon 7. MST2 ∆7 exhibited increased ubiquitylation and interaction with the E3 ubiquitin-protein ligase CHIP compared to the full-length protein (MST2 FL ). Exon 7 in STK3 encodes a segment within the kinase domain, and its exclusion compromised MST2 interaction with and phosphorylation of MOB, a major MST1/2 substrate. Nevertheless, MST2 ∆7 was capable of interacting with MST1 and MST2 FL . Unlike MST2 FL , overexpression of MST2 ∆7 did not lead to increased cell death and growth arrest. Strikingly, we observed the exclusion of STK3 exon 7 in 3.2–15% of tumor samples from patients of several types of cancer, while STK3 ∆7 was seldomly found in healthy tissues. Our study identified a novel STK3 splicing variant with loss of function and the potential to disturb tissue homeostasis by impacting on MST2 activities in the regulation of cell death and quiescence.
oncology,genetics & heredity,biochemistry & molecular biology,cell biology